Inside Cytonics’ Breakthrough Year: 2023 Recap & 2024 Outlook
Join us as we reflect on a year of innovation and look forward to the promising developments on the horizon.
From the entire Cytonics team, I’d like to wish you and your families a Happy Holiday and New Year! 2023 has been a turbulent year for many, marked by layoffs, recession fears, and high interest rates. Yet, the capital markets have never been more bullish, with the S&P hitting historic highs in December. The Biotech sector has also benefited from this positive sentiment, with the XBI (a biotechnology SPDR ETF) up 20% over the last 30 days! Cytonics has also rode this positive sentiment, with over $1,000,000 invested from 400+ investors within the first 3 weeks of our equity crowdfunding campaign.
All signs point to a strong 2024 in biotech, which will be marked by (1) increased M&A activity as Big Pharma is pressured to spend the cash they hoarded during COVID in the face of looming patent expirations, (2) an uptick in IPOs as many companies delayed going public due to unfavorable market conditions, and (3) a higher volume of Venture Capital investment as the IPO window opens back up and the sector generally becomes more “risk-on.”
✨ The tide is turning. 2024 will be the year for biotech (and Cytonics)!
All of these factors bode very well for Cytonics, as our Phase 1 clinical trial data will be unlocked in early Q1 2025. Then, the search begins for path towards exit. This will come in the form of either (1) a strategic partner to co-develop our lead osteoarthritis drug candidate, CYT-108, through Phase 2 clinical studies. This timing could be *perfect*, as valuations across the sector rise and Pharma becomes more acquisitive to fill their R&D pipelines. Or, (2) we file for an Initial Public Offering after the Phase 1 data is unlocked with the intention of raising $30M to fund the Phase 2 ourselves. The timing of a 2025 IPO could be *perfect*, as public offerings will have gained more steam and the market’s appetite for early-stage assets will have heightened by then.
And while all of this is speculative, and no guarantee, what I do know is that we are sailing into 2024 with strong tailwinds at our backs. We are on the cusp of the single biggest milestone in our company’s entire history, and a major valuation inflection point: our first-in-human Phase 1 clinical study. If approved by the FDA, our lead drug candidate for osteoarthritis, CYT-108, will likely be the first and only disease-modifying treatment for osteoarthritis…
🏆 The Holy Grail of Regenerative Medicine that has eluded Big Pharma for decades is within our grasp.
A bit of gratitude is in order. A sincere “Thank You” to all our valued shareholders who have made our success possible. Drug development is an incredibly difficult, exciting, and rewarding endeavor. There are millions of people waiting for this treatment, and the promise of significantly improving human well-being is all the motivation we need! ❤️ We are truly grateful to have you along for the ride. As always, do not hesitate to contact us: Joey Bose, President and CEO, joey.bose@cytonics.com.
In our next post, you’ll learn how a UFC legend who saved his career with our APIC therapy!
Ready to become a shareholder? Visit invest.cytonics.com.
This communication may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they contain hypothetical illustrations of mathematical principles, are meant for illustrative purposes, and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.
Leave a Reply